Cara Therapeutics to Participate in Webcast on Pain Targeting Mechanisms

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and Chief Executive Officer, will participate in a webcast featuring innovations in pain management therapies. The webcast is part of a series from Biopharma Dealmakers, a quarterly supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

Four companies that are working to address unmet needs in pain management will present their developments, which include analgesics with novel mechanisms of action, medical devices, and opioids with reduced potential for abuse and physical dependence. The webcast will also include a roundtable discussion and a question and answer session with Dr. Chalmers and the other speakers.

Details for the webcast are as follows:

Date:  Thursday, October 6, 2016Time:  11:00 a.m. ETModerator:  Raveena Bhambra, Editor of BioPharma DealmakersParticipants:

• Dr. Derek Chalmers, President and CEO of Cara Therapeutics
• Dr. Jeffrey Herz, President and CEO of Algomedix, Inc.
• Dr. Jessica Preciado, Director of Product Development and Principal Scientist of Myoscience
• Dr. Steve Doberstein, Senior Vice President and Chief Scientific Officer of Nektar Therapeutics

For more information, and to register for this free webcast, visit: http://www.workcast.com/register?cpak=5922214840089056&referrer=SPONSOR_CaraTherapeutics.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200 
[e-mail]

MEDIA CONTACT: 
Annie Starr
6 Degrees
973-415-8838 
[e-mail]